Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma.
Cancer Cell, 2011/8/16;20(2):143-57.
Witt H[1], Mack SC, Ryzhova M, Bender S, Sill M, Isserlin R, Benner A, Hielscher T, Milde T, Remke M, Jones DT, Northcott PA, Garzia L, Bertrand KC, Wittmann A, Yao Y, Roberts SS, Massimi L, Van Meter T, Weiss WA, Gupta N, Grajkowska W, Lach B, Cho YJ, von Deimling A, Kulozik AE, Witt O, Bader GD, Hawkins CE, Tabori U, Guha A, Rutka JT, Lichter P, Korshunov A, Taylor MD, Pfister SM
Affiliations
PMID: 21840481DOI: 10.1016/j.ccr.2011.07.007
Impact factor: 38.585
Abstract
Despite the histological similarity of ependymomas from throughout the neuroaxis, the disease likely comprises multiple independent entities, each with a distinct molecular pathogenesis. Transcriptional profiling of two large independent cohorts of ependymoma reveals the existence of two demographically, transcriptionally, genetically, and clinically distinct groups of posterior fossa (PF) ependymomas. Group A patients are younger, have laterally located tumors with a balanced genome, and are much more likely to exhibit recurrence, metastasis at recurrence, and death compared with Group B patients. Identification and optimization of immunohistochemical (IHC) markers for PF ependymoma subgroups allowed validation of our findings on a third independent cohort, using a human ependymoma tissue microarray, and provides a tool for prospective prognostication and stratification of PF ependymoma patients.
MeSH terms
Adult; Brain Neoplasms; Chromosome Aberrations; Cranial Fossa, Posterior; Ependymoma; Female; Gene Expression Profiling; Humans; Male; Middle Aged
More resources
Full text:
Europe PubMed Central; PubMed Central
EndNote: Download